|Day Low/High||3.96 / 4.18|
|52 Wk Low/High||2.15 / 5.78|
We took advantage of the relative weakness in the small-cap universe to add two new names to the model portfolio this week.
Despite the risky nature of the biotech sector, this company has the potential to be a Game Breaker.
Orexigen Therapeutics' 3rd-quarter loss narrows on lower costs following Contrave studies
Gregg Greenberg hosts. Guests include Tim Guinness, portfolio manager for the Guinness Atkinson Global Energy Fund, Lynne Ford, head of retail retirement for Wells Fargo, David Peltier, TheStreet.com's Stocks Under $10 portfolio manager and Richard Peterson, Director of Credit, Markets and Risk for S&P.
Earnings roundup: GMAC loss narrows as auto lending profitable, Molson Coors profit grows
Vivus shares dive after 3rd-quarter report, but Wall Street remains focused on obesity drug
Japanese drugmaker Takeda licenses worldwide rights to Amylin weight-loss pipeline.
Amylin Pharmaceuticals signs weight-loss drug deal with Takeda potentially worth over $1B
At issue are cognitive side effects for Vivus' weight-loss drug Qnexa
Here's how some of Monday's 'Mad Money' stocks fared on Tuesday.
Cramer says it's a terrific bank that is favored by regulators.
Cramer said the Dow cannot rally past 10,000 without a solid improvement in earnings. Click for news from Jim Cramer.
Cramer says investors can take advantage of a production glitch in iPhones to buy Apple on Tuesday, the day after its earnings report. Click for news from Jim Cramer.
Readers touch base with Adam on Transdel Pharma, Vivus, Genta, Cel-Sci and more.
Stick with the stocks that have already told us they're doing well, and watch out for the battle of macro economic data: retail sales vs. jobless. Click for news from Jim Cramer.
Orexigen Therapeutics, Vivus shares gain ground on obesity drug study data
Why wait one week to discuss good breast cancer data?
A quick and dirty guide to important biotech events for October.
Orexigen Therapeutics' obesity drug candidate meets weight loss goal in midstage study
A midstage study of Empatic demonstrates significant weight loss.
After Arena report, Arena and Virus shares rise as analysts assess prospects for obesity drugs
Arena weight drug lorcaserin meets goals, but comes up short against rival drug candidates
Patients taking lorcaserin lost a placebo-adjusted 3.1% of their body weight after one year. But that stat falls short of the 5% placebo-adjusted weight loss benchmark that many doctors believe is clinically meaningful.
Big Pharma is seeking deals with biotech, specialty pharma, analyst says
Analyst thinks sales of Arena's lorcaserin will trail other obesity drugs, downgrades stock
Bulls and bears prepare for Arena Pharma's obesity drug trial results.
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.